Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
NEW YORK - Stryker Corporation (NYSE:SYK) reported first-quarter 2025 results that surpassed analyst expectations, driven by strong procedural volumes and demand for its capital products. The medical technology company also raised its full-year organic sales growth guidance.
Stryker reported adjusted earnings per share (EPS) of $2.84 for the first quarter, beating the analyst estimate of $2.71. Revenue came in at $5.9 billion, exceeding the consensus estimate of $5.68 billion and representing an 11.9% increase YoY.
The company’s organic net sales grew 10.1% in the quarter, including a 9.4% increase from higher unit volume and a 0.7% rise from increased prices. MedSurg and Neurotechnology net sales rose 13.4% to $3.5 billion, while Orthopaedics net sales increased 9.7% to $2.4 billion.
Stryker’s shares remained flat following the earnings release.
"Our 2024 momentum continued into the first quarter as we delivered double-digit organic sales growth and continued to expand adjusted operating margins," said Kevin A. Lobo, Chair and CEO of Stryker.
Looking ahead, Stryker raised its full-year 2025 organic net sales growth guidance to a range of 8.5% to 9.5%, up from its previous forecast. The company now expects adjusted EPS for the year to be between $13.20 and $13.45, compared to the analyst consensus of $13.45.
The updated guidance incorporates the dilutive impact of the Inari Medical (TASE:BLWV) acquisition and offsets an estimated $200 million tariff impact, based on current information and estimates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.